HPV and cervical cancer.

Area of Science:

• Gynecology
• Oncology
• Preventive Medicine

Background:

• Cervical cancer is a leading global cancer in women, with increasing incidence despite being preventable.
• Persistent infection with human papillomavirus (HPV) is the primary cause of cervical cancer.
• Current screening with cytology smears is effective but generates many false positives and unnecessary treatments.

Purpose of the Study:

• To evaluate the feasibility of improving cervical cancer prevention through HPV screening and vaccination.
• To assess the potential reduction in new cancer cases and screening interventions.

Main Methods:

• Review of global cancer burden data and evidence from randomized controlled trials.
• Analysis of the efficacy of HPV vaccination and HPV screening strategies.
• Emphasis on colposcopy as the gold standard for managing abnormal findings.

Main Results:

• Shifting to HPV screening in women aged 30+ could reduce new cervical cancer cases by 70-80%.
• HPV vaccination prevents approximately 80% of cervical cancer precursors.
• Integrated HPV vaccination and screening strategies offer near-eradication potential for cervical cancer.

Conclusions:

• Improved cervical cancer prevention is achievable through HPV-based screening and vaccination.
• A combined approach significantly reduces cancer incidence, screening burden, and other HPV-related diseases.
• Optimized patient pathways and quality-assured colposcopy are crucial for effective management.